ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Janus kinase (JAK)"

  • Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting

    The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study

    Axel Finckh1, Christophe Tellenbach2, Almut Scherer2, Burkhard Moeller3, Adrian Ciurea4, Ines von Mühlenen5, Cem Gabay6, Diego Kyburz7, Ruediger Mueller8, Paul Hasler9 and Pascal Zufferey10, 1University Hospital of Geneva, Geneva, Switzerland, 2SCQM Foundation, Zurich, Switzerland, 3Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Rheuma-Basel, Basel, Switzerland, 6University Hospitals of Geneva, Geneva, Switzerland, 7Rheumatology, University Hospital Basel, Basel, Switzerland, 8Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, 9Kantonsspital Aarau AG, Aarau, Switzerland, 10Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland

    Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
  • Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting

    Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial

    Thomas Dörner1, Yoshiya Tanaka2, Michelle Petri3, Josef S. Smolen4, Ernst R. Dow5, Richard E. Higgs5, Robert J. Benschop5, Adam Abel5, Maria E. Silk5, Stephanie de Bono5 and Robert W. Hoffman5, 1Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 5Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
  • Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting

    Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)

    Bruno Fautrel1, Baojin Zhu2, Peter C. Taylor3, Mart van de Laar4, Paul Emery5, Francesco de Leonardis2, Carol L. Gaich2, Claudia Nicolay2, Zbigniew Kadziola2, Inmaculada de la Torre6 and Roy Fleischmann7, 1University Pierre et Marie Curie, Paris, France, 2Eli Lilly and Company, Indianapolis, IN, 3Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, 4Arthritis Centre Twente, University of Twente, Enschede, Netherlands, 5Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, 6Eli Lilly and Company, Madrid, Spain, 7Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
  • Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting

    Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis

    Christian S. Thudium1, Anne C. Bay-Jensen1, Suntara Cahya2, Ernst R. Dow2, Morten A. Karsdal1, Alisa E. Koch2, Wenling Zhang2 and Robert J. Benschop2, 1Nordic Bioscience, Herlev, Denmark, 2Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
  • Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Sakae Tanaka3, Atsushi Kawakami4, Manabu Iwasaki5, Yeong Wook Song6, Yi-Hsing Chen7, Mitsuhiro Rokuda8, Hiroyuki Izutsu8, Satoshi Ushijima8, Yuichiro Kaneko8, Teruaki Shiomi8 and Emi Yamada8, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Nagasaki University, Nagasaki, Japan, 4University of Tokyo, Tokyo, Japan, 5Yokohama City University, Yokohama, Japan, 6Seoul National University Hospital, Seoul, Korea, Republic of (South), 7Taichung Veterans General Hospital, Taichung City, Taiwan, 8Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
  • Abstract Number: 2065 • 2018 ACR/ARHP Annual Meeting

    Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis

    Yukiko Maeda1, Zheni Stavre1, Tingting Huang2, Catherine Manning2, Bryant Shaughn3, Michael Macoritto3, Deborah Hyland3, Wendy Waegell3 and Ellen M. Gravallese4, 1Medicine, University of Massachusetts Medical School, Worcester, MA, 2Medicine, University of Massachusetts Medical School, worcester, MA, 3Abbvie Bioresearch Center, worcester, MA, 4Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Spondyloarthritis (SpA) results in significant pain and loss of function due to inflammation and resulting enthesial/periosteal bone formation. Inhibition of the Janus kinase (JAK)/STAT…
  • Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate

    Tsutomu Takeuchi1, Yoshiya Tanaka2, Sakae Tanaka3, Atsushi Kawakami4, Manabu Iwasaki5, Mitsuhiro Rokuda6, Hiroyuki Izutsu6, Satoshi Ushijima6, Yuichiro Kaneko6, Teruaki Shiomi6 and Emi Yamada6, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Nagasaki University, Nagasaki, Japan, 4University of Tokyo, Tokyo, Japan, 5Yokohama City University, Yokohama, Japan, 6Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
  • Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting

    Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus

    Pei Han1, Christopher Pohlmeyer1, Ching Shang1, Zhihua Cui2, David Lopez3, Astrid Clarke2, Randall Jones2, Nevena Mollova3, Igor Mikaelian4, David Newstrom3, Shiva Zaboli3, Allyson Shauf3 and Julie Di Paolo5, 1Immunology and Inflammation, Gilead Sciences, Foster City, CA, 2Gilead Sciences, Seattle, WA, 3Gilead Sciences, Foster City, CA, 4Biology Core Support, Gilead Sciences, Foster City, CA, 5Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…
  • Abstract Number: 889 • 2018 ACR/ARHP Annual Meeting

    Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

    Josef S. Smolen1, Stanley Cohen2, Paul Emery3, William F C Rigby4, Yoshiya Tanaka5, Ying Zhang6, Alan Friedman6, Ahmed A. Othman6, Heidi S. Camp6 and Aileen L. Pangan6, 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 2Metroplex Clinical Research Center, Dallas, TX, 3Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, United Kingdom, 4Dartmouth College, Hanover, NH, 5Univ of Occupational and Environmental Health, Kitakyushu, Japan, 6AbbVie, North Chicago, IL

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing…
  • Abstract Number: 2103 • 2018 ACR/ARHP Annual Meeting

    Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus

    Nathan Mortimer, Mary Fischer, Ashley Waring and Victoria DeMichel, School of Biological Sciences, Illinois State University, Normal, IL

    Background/Purpose: The objective of our research is to understand the genetic architecture and molecular mechanisms that contribute to the development and progression of the autoimmune…
  • Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting

    Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor

    Mark C. Genovese1, Roy Fleischmann2, Bernard Combe3, Stephen Hall4, Ying Zhang5, Yijie Zhou5, Mohamed-Eslam F. Mohamed6, Sebastian Meerwein7 and Aileen L. Pangan5, 1Stanford University Medical Center, Palo Alto, CA, 2University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 3Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 4Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, 5AbbVie Inc., North Chicago, IL, 6Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

    Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
  • Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting

    Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs

    Philip J Mease1, Joel Kremer2, Stanley Cohen3, Jeffrey R Curtis4, Christina Charles-Schoeman5, Edward V Loftus6, Jeffrey D Greenberg7, Niki Palmetto8, Keith S Kanik9, Daniela Graham9, Cunshan Wang9, Pinaki Biswas8, Gary Chan10, Ryan DeMasi10, Hernan Valdez8, Thijs Hendrikx10 and Thomas V Jones10, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 3Metroplex Clinical Research Center, Dallas, TX, 4University of Alabama, Birmingham, AL, 5University of California, Los Angeles, CA, 6Mayo Clinic, Rochester, MN, 7Corrona, LLC, Southborough, MA, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
  • Abstract Number: 510 • 2017 ACR/ARHP Annual Meeting

    Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies

    Mark C. Genovese1, Annegret Van der Aa2, Corinne Jamoul2, Chantal Tasset2, Pille Harrison2, René Westhovens3 and Arthur Kavanaugh4, 1Stanford University Medical Center, Palo Alto, CA, 2Galapagos NV, Mechelen, Belgium, 3University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, 4Medicine, University of California, San Diego, La Jolla, CA

    Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
  • Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting

    Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice

    Rachel Twomey1, Stuart Perper1, Susan Westmoreland1, Terry Melim1, Soumya Mitra1, Zheng Liu1, Manuel Duval1, Carolyn Cuff2, Andrew Long1, Anthony Slavin2 and Stephen Clarke1, 1AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2Immunology Discovery, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…
  • Abstract Number: 511 • 2017 ACR/ARHP Annual Meeting

    Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis

    Mark C. Genovese1, Josef S. Smolen2, Tsutomu Takeuchi3, David Hyslop4, William L. Macias4, Terence P. Rooney4, Lei Chen4, Christina L. Dickson4, Jennifer Riddle Camp4, Tracy Cardillo4, Taeko Ishii5 and Kevin Winthrop6, 1Stanford University Medical Center, Palo Alto, CA, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Kobe, Japan, 6Oregon Health & Science University, Portland, OR

    Background/Purpose:  Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved in the EU for the treatment of moderately…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology